(Q64969820)

English

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.

scientific article published on 17 April 2019

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

author name string

Hiddo J L Heerspink

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Skander Mulder

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Johannes Leierer

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Michael K Hansen

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Andreas Heinzel

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Gert Mayer

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

publication date

17 April 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

62

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

1154-1166

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

copyright license

Creative Commons Attribution 4.0 International

17 April 2019

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proximal tubule in the pathophysiology of the diabetic kidney

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kidney disease and increased mortality risk in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT2 inhibitors: β blockers for the kidney?

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Study of IL4-590C/T and IL6-174G/C Gene Polymorphisms in Type 2 Diabetic Patients With Chronic Kidney Disease in North Indian Population.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes Mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High Glucose Reduces Megalin-Mediated Albumin Endocytosis in Renal Proximal Tubule Cells through Protein Kinase B O-GlcNAcylation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Astilbin inhibits high glucose-induced autophagy and apoptosis through the PI3K/Akt pathway in human proximal tubular epithelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/31001673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-019-4859-4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31001673%20AND%20SRC:MED&resulttype=core&format=json

10 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64969820&oldid=1886466935"